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Despite the unprecedented success of tyrosine kinase inhibitors (TKI), clinical management 
of 20-30% of chronic myeloid leukemia (CML) patients experiencing primary or secondary 
resistance to Imatinib mesylate (IM) continues to be challenging [1-3]. Early identification of 
these patients would indicate a more potent agent upfront or alternative drug following initial 
sub-optimum response or SCT prior to the subject becoming refractory to further treatment. 
Therefore a biomarker with proven clinical utility of predicting patients’ response to IM 
would assist considerably in optimizing clinical management for such patients. Recently 
investigators reported Src homology 2 domain-containing phosphates-1 (SHP-1) expression 
levels at diagnosis were prognostic and predictive of TKI response in CML patients [4]. 
Previously others suggested down regulation of SHP-1 contributes to constitutive activation 
of Jak/Stat signaling and disrupts protein phosphatase 2A (PP2A) mediated BCR-ABL11 
elimination thereby triggering CML transformation [5] (Neviani et al, 2005). 
Therefore we retrospectively studied 97 cDNA samples from highly heterogenous CML 
patients to assess the clinical utility of measuring SHP-1 mRNA levels in CML patients 
(Table I). The samples were collected at various time points, reflected by the overlap in 
BCR-ABL1 transcript numbers for those who achieved major molecular response and those 
who did not (Table I). Of the 97 patients 24 were in advanced disease phase (AD), i.e. 
accelerated phase (AP); n=6 and blast crisis (BC); n=18 and 73 highly heterogenous patients 
in CP treated with different modalities. For 35 of the 73 CP patients the major molecular 
responses (MMR) status was available for assessing the clinical utility SHP-1 levels. From 
among the 24 patients in AD at least 5 archived serial mRNA samples were available for 
each of the 5 patients for longitudinal studies. Of these 5 patients four had been treated with 
one or more tyrosine kinase inhibitors (TKI) and one had allogenic stem cells transplant 
(SCT). We also included a cohort control of 77 diagnostic samples from heterogeneous 
group of AML patients and 18 normal controls samples from adult volunteer blood donors’ 
characteristics are detailed in Table I. 
SHP1, BCR-ABL1 and endogenous control gene, GUSβ transcripts were quantified by real 
time polymerase chain reaction as previously reported [6]. Standard curves, were 
constructed for each assay using serial log dilutions of plasmid, ranging from 1x103 to 1x106, 


































































plasmid and the other included the SHP-1 insert (kind gift from Professor F. Pane, Naples, 
Italy). Only those samples with ≥5500 GUSβ transcripts were evaluated for this report. Non-
parametric Mann Whitney were performed using PRISM software. 
Briefly, 38 of the 73 CP patients were prescribed single agents; interferon and cytarabine 
(n=1), Imatinib (n=30); nilotinib (n=6) and dasatinib (n=1). The remainder were treated with 
2 or more agents, as were the 24 AD patients. SHP-1 mRNA was detectable in all the 
samples screened by Q-PCR (Table I). However, significant differential in mRNA 
expression (p<0.0001) was observed between patients in CP and the normal control group. 
Furthermore, the SHP-1 transcripts were significantly lower (p=0.0001) in AD patients with 
median of 14.0 (range 0.8 to 211.9), in comparison to patients in CP, median 35.7 (range: 
5.2-675.1). Similarly, we observed a significant difference between CML patients in AD and 
normal control samples, p<0.0001. But we observed no significant difference in SHP-1 
levels between AML and NC samples (p=0.801). This is probably explained by molecular 
heterogeneity among the AML patients in contrast to the single genetic lesion associated 
with CML and SHP-1 is reported to bind to BCR-ABL1. 
In contrast to published data [4] we found no significant difference, p=0.0966, between the 
patients who failed to achieve MMR within 18 months (n=22) and those patients who did 
(n=13). To exclude the possibility that the statistical value might have been influenced by 
either the highly variable collection time points or the diverse therapeutic agents 
administered, a restricted analysis of 15 patients treated with IM alone and for whom we had 
samples collected at diagnosis was performed. Even within this group we found no 
significant difference p=0.4527, i.e. not significant between those who did (n=6) and failed 
(n=9) achieve MMR within 12 months. This did not change even if the criterion was 
extended to 18 months. This variance from published data may reflect the differences in 
timing of the sample collection during course of the treatment in this study and that reported 
by Esposito et al [4]. But these data to not exclude the possibility that assessing SHP-1 
activity at protein level would be predictive. But protein analysis are too complex for a 
clinical laboratory to perform, in contrast to Q-PCR analysis, and therefore not within the 


































































In addition we noted no significant difference in SHP-1 mRNA levels between those patients 
in CP who had been prescribed 1 (n=37), 2 (n=7), or ≥ 3 TKI (n=8), which generally 
correlates with optimal, sub-optimal and/or failed response. 
The kinetics data was consistent with overall CP and AD results, showing SHP-1 levels 
decrease as the BCR-ABL1 transcript numbers increased, i.e. an inverse relationship (Figure 
1), implying regulatory control of two is directly or indirectly linked. We did note that for 
Patient 4, including the period when the subject was in CP (Figure 1), this relationship was 
not observed. However there was no difference of note in this patient’s clinical history 
compared to the other 4 subjects. More importantly, BCR-ABL1 transcripts in these 5 
patients were not preceded by a decrease in SHP-1. 
Given the relatively low levels of SHP-1 in comparison to BCR-ABL1 expression, we 
confirmed our assay could reproducibly detect a 5 fold change in SHP-1 mRNA levels by 
titrating, in duplicate, SU-DHL-1 cell line with LAMA-87 haematopoietic cell line. 
Consistent with the generally accepted view that Q-PCR assays have a dynamic range of 5 
logs, although up to 8 logs range is achievable. 
Therefore, the kinetics and MMR data suggest measuring SHP-1 mRNA level does not 
provide added information in identifying patients at risk of disease progression or predict 
response to TKI beyond that gleaned from close regular monitoring by measuring disease 
specific BCR-ABL1 transcripts. However, differential expression of SHP-1 between CP and 
AD observed in this study was consistent with earlier reports suggesting the phosphatase 
antagonises BCR-ABL1 ability to block differentiation [7, 8]. A reduced expression of 
SHP-1 might free BCR-ABL1 to recruit and activate JAK2. Activate JAK2 has been reported 
to enhance β-catenin activity and inactivates PP2A mediated degradation of the BCR-ABL1 
thus triggering BC [9] 
In conclusion, our data imply SHP-1 levels fail to predict TKI response. But in keeping with 
previous reports our data provides further evidence to support the notion that SHP-1 plays a 
role in CML disease progression. 
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Fig. 1. SHP-1 and BCR-ABL1 kinetics. The Kinetics data for SHP-1 (dashed lines) and 
BCR-ABL1 (solid lines) are shown for the 5 CML patients included in the longitudinal study. 
The Y axis for the SHP-1 levels are on the right of each graph. SHP-1 mRNA was detected 
in all samples tested for the 5 patients and reflected the BCR-ABL1 kinetics. SHP-1 levels 
did not predict a change in the patients’ disease status, such that an increase or decrease in its 
expression did not precede a change in BCR-ABL1 transcript levels. Therefore, we concluded 
its predictive value was not superior to that of disease specific marker, BCR-ABL1. 
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